Learn about a new line of treatment for uveitis – the third leading cause of blindness in developed nations. While corticosteroids and other corticosteroid-sparing agents have been widely used in management of noninfectious uveitis, this Focal Points module focuses on a newer line of therapy termed biologic agents. Biologic agents have shown efficacy as primary therapy for uveitis or as secondary corticosteroid-sparing agents. Biologic agents are increasingly being used not only for uveitis, but also for treatment of other inflammatory ocular diseases. With peak onset for uveitis occurring between 20 and 40 years of age among working individuals, it is important to know the latest about treating this significant public health concern.
Upon completion of this Focal Points module, you should be able to:
- Demonstrate understanding of the current range of biologic agents available for the treatment of uveitis and ocular inflammatory disease.
- Describe the side effects associated with the biologic agents.
- Be aware of the newer biologic agents on the horizon that may be useful in clinical practice for the treatment of inflammatory eye diseases.
Focal Points issues are practical, hands-on discussions of the clinical challenges you face daily. Each issue delivers high-quality, trusted ophthalmic information written and reviewed by leading experts.
Subscribers receive 12 new issues a year, plus access to the Focal Points digital archive.
To access this issue from your laptop or desktop computer, log in to www.aao.org/myonlineproducts with your Academy username and password. To access this issue from your Apple iPad® or Android™ tablet, use the free AAO eBooks app. For more information about the app, visit www.aao.org/ebooks.
The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Once you have completed this Focal Points issue, please visit CME Central to review or claim your CME.